AnaptysBio (NASDAQ:ANAB) Shares Gap Up – Here’s What Happened

AnaptysBio, Inc. (NASDAQ:ANAB)’s share price gapped up prior to trading on Tuesday . The stock had previously closed at $16.66, but opened at $17.45. AnaptysBio shares last traded at $17.22, with a volume of 119,104 shares trading hands.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. Wolfe Research assumed coverage on shares of AnaptysBio in a report on Tuesday. They issued an “outperform” rating and a $25.00 price objective for the company. BTIG Research cut shares of AnaptysBio from a “buy” rating to a “neutral” rating in a report on Monday, December 2nd. UBS Group upped their target price on AnaptysBio from $23.00 to $33.00 and gave the company a “neutral” rating in a report on Wednesday, October 30th. Wells Fargo & Company lowered their price objective on AnaptysBio from $56.00 to $40.00 and set an “overweight” rating for the company in a research note on Thursday, December 12th. Finally, Guggenheim reduced their price target on shares of AnaptysBio from $90.00 to $36.00 and set a “buy” rating for the company in a report on Thursday, December 12th. Four research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, AnaptysBio has an average rating of “Moderate Buy” and a consensus price target of $40.08.

AnaptysBio Trading Down 2.7 %

The business has a fifty day moving average of $17.05 and a 200-day moving average of $26.77.

AnaptysBio (NASDAQ:ANAB) last released its earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) EPS for the quarter, topping analysts’ consensus estimates of ($1.72) by $0.58. The business had revenue of $30.02 million for the quarter, compared to the consensus estimate of $7.92 million. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. Analysts anticipate that AnaptysBio, Inc. will post -6.08 EPS for the current year.

Insider Transactions at AnaptysBio

In other news, Director Ecor1 Capital, Llc purchased 65,184 shares of the business’s stock in a transaction dated Monday, December 30th. The shares were acquired at an average price of $12.92 per share, for a total transaction of $842,177.28. Following the completion of the acquisition, the director now directly owns 7,860,180 shares of the company’s stock, valued at $101,553,525.60. The trade was a 0.84 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 33.70% of the company’s stock.

Institutional Trading of AnaptysBio

Several large investors have recently added to or reduced their stakes in the company. Y Intercept Hong Kong Ltd acquired a new position in AnaptysBio during the fourth quarter valued at $311,000. Rhumbline Advisers lifted its position in shares of AnaptysBio by 3.8% in the fourth quarter. Rhumbline Advisers now owns 30,077 shares of the biotechnology company’s stock worth $398,000 after purchasing an additional 1,111 shares in the last quarter. Jennison Associates LLC boosted its holdings in shares of AnaptysBio by 1.6% during the fourth quarter. Jennison Associates LLC now owns 269,131 shares of the biotechnology company’s stock worth $3,563,000 after purchasing an additional 4,242 shares during the period. China Universal Asset Management Co. Ltd. grew its position in AnaptysBio by 11.1% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,452 shares of the biotechnology company’s stock valued at $85,000 after purchasing an additional 644 shares in the last quarter. Finally, SG Americas Securities LLC increased its stake in AnaptysBio by 35.0% in the 4th quarter. SG Americas Securities LLC now owns 16,307 shares of the biotechnology company’s stock valued at $216,000 after buying an additional 4,231 shares during the period.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.